



## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:

Elan Pharmaceuticals, Inc.

FILING DATE

06/15/00

GROUP

1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>[Signature]</i>	P1	4709010	11/24/87	Holzemann	530 323	10/18/85
	P2					
	P3					
	P4					
	P5					
	P6					
	P7					
	P8					
	P9					
	P10					
	P11					

RECEIVED  
DEC 20 2001  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>[Signature]</i>	F1	WO 97/30072	8/27/97	WIPO			
	F2						
	F3						
	F4						
	F5						

## OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>[Signature]</i>	D1	Majer, Pavel, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors" <i>Protein Science</i> , 6:1458-1466 (1977).
	D2	

EXAMINER

*[Signature]* *[Signature]*

DATE CONSIDERED

6/21/02

EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.